The US FDA Reverses Decision And Allows Oxitriptan Compounding For Now
Executive Summary
The US FDA says new information brought to light by pharmacists and caregivers on compounded oxitriptan prompted the agency to reconsider its decision to exclude the substance from the 503A bulks list. Oxitriptan was placed on the do not compound list in February.